FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2176045506> ?p ?o ?g. }

• W2176045506 abstract "According to the guidelines of the European Association for the Study of the Liver (EASL), patients affected from hepatocellular carcinoma (HCC) can be classified according to the Barcelona Clinic Liver Cancer (BCLC) staging system. This classification system divides HCC patients in five stages (0, A, B, C and D) on the basis of a number of prognostic and treatment- related variables such as tumor status and liver function. A specific treat ment approach is then proposed for each of the above-mentioned stages. Transarterial chemoembolization (TACE) is recommended as first-line therapy in the treatment of patients with intermediate-stage (BCLC-B class) HCC [1]. The efficacy of this procedure is supported by robust data [2,3]. Despite its efficacy, however, there is still a lack of standardization in treatment methodology, and TACE protocols are widely variable both in terms of dosages and schedule (on demand vs fixed interval administration) [4]. Moreover, the longterm outcomes of patients managed with TACE are not fully satisfactory, with up to 80% of patients eventually showing tumor progression [5] and TACE can be associated with a number of contraindications [4]. Of note, patients with BCLC-B HCC present highly heterogenic features, and therefore the behavior of intermediate-stage HCC patients is difficult to anticipate [6,7]. This heterogeneity is due to a number of characteristics including performance status, Child-Pugh class and presence of portal vein thrombosis. Therefore, the development of an effective treatment strategy for all patients with BCLC-B HCC does not appear to be an easy task: a tailored approach to optimize the clinical outcomes in each single patient is needed [8]. Treatment options different from TACE, such as surgery, local ablation, radioembolization or systemic therapy, may be effective in patients with intermediate- stage HCC, and research in this filed appears quite active [8]. One of the most promising treatment options is the combination of different therapies [8,9]. Sorafenib, an oral multityrosine kinase inhibitor, is the only systemic therapy to be approved in patients with HCC [10]. Current guidelines and expert opinions recommend the use of sorafenib in patients" @default.
• W2176045506 created "2016-06-24" @default.
• W2176045506 creator A5011265052 @default.
• W2176045506 creator A5028046087 @default.
• W2176045506 creator A5038697021 @default.
• W2176045506 creator A5058563905 @default.
• W2176045506 creator A5065825652 @default.
• W2176045506 creator A5073493755 @default.
• W2176045506 date "2015-09-01" @default.
• W2176045506 modified "2023-09-24" @default.
• W2176045506 title "Transarterial chemoembolization and sorafenib in patients with intermediate-stage hepatocellular carcinoma: time to enter routine clinical practice?" @default.
• W2176045506 cites W1967863345 @default.
• W2176045506 cites W1975154077 @default.
• W2176045506 cites W1979465904 @default.
• W2176045506 cites W1996703005 @default.
• W2176045506 cites W2000346327 @default.
• W2176045506 cites W2017188169 @default.
• W2176045506 cites W2024450952 @default.
• W2176045506 cites W2029029081 @default.
• W2176045506 cites W2031606631 @default.
• W2176045506 cites W2043162780 @default.
• W2176045506 cites W2049811920 @default.
• W2176045506 cites W2051193106 @default.
• W2176045506 cites W2054887165 @default.
• W2176045506 cites W2089570379 @default.
• W2176045506 cites W2171673899 @default.
• W2176045506 cites W4245784696 @default.
• W2176045506 doi "https://doi.org/10.2217/fon.15.173" @default.
• W2176045506 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26270206" @default.
• W2176045506 hasPublicationYear "2015" @default.
• W2176045506 type Work @default.
• W2176045506 sameAs 2176045506 @default.
• W2176045506 citedByCount "10" @default.
• W2176045506 countsByYear W21760455062016 @default.
• W2176045506 countsByYear W21760455062017 @default.
• W2176045506 countsByYear W21760455062018 @default.
• W2176045506 countsByYear W21760455062019 @default.
• W2176045506 countsByYear W21760455062020 @default.
• W2176045506 crossrefType "journal-article" @default.
• W2176045506 hasAuthorship W2176045506A5011265052 @default.
• W2176045506 hasAuthorship W2176045506A5028046087 @default.
• W2176045506 hasAuthorship W2176045506A5038697021 @default.
• W2176045506 hasAuthorship W2176045506A5058563905 @default.
• W2176045506 hasAuthorship W2176045506A5065825652 @default.
• W2176045506 hasAuthorship W2176045506A5073493755 @default.
• W2176045506 hasConcept C126322002 @default.
• W2176045506 hasConcept C126838900 @default.
• W2176045506 hasConcept C143998085 @default.
• W2176045506 hasConcept C146357865 @default.
• W2176045506 hasConcept C151730666 @default.
• W2176045506 hasConcept C2776231280 @default.
• W2176045506 hasConcept C2778019345 @default.
• W2176045506 hasConcept C2778695046 @default.
• W2176045506 hasConcept C2992208098 @default.
• W2176045506 hasConcept C71924100 @default.
• W2176045506 hasConcept C86803240 @default.
• W2176045506 hasConcept C90924648 @default.
• W2176045506 hasConceptScore W2176045506C126322002 @default.
• W2176045506 hasConceptScore W2176045506C126838900 @default.
• W2176045506 hasConceptScore W2176045506C143998085 @default.
• W2176045506 hasConceptScore W2176045506C146357865 @default.
• W2176045506 hasConceptScore W2176045506C151730666 @default.
• W2176045506 hasConceptScore W2176045506C2776231280 @default.
• W2176045506 hasConceptScore W2176045506C2778019345 @default.
• W2176045506 hasConceptScore W2176045506C2778695046 @default.
• W2176045506 hasConceptScore W2176045506C2992208098 @default.
• W2176045506 hasConceptScore W2176045506C71924100 @default.
• W2176045506 hasConceptScore W2176045506C86803240 @default.
• W2176045506 hasConceptScore W2176045506C90924648 @default.
• W2176045506 hasLocation W21760455061 @default.
• W2176045506 hasLocation W21760455062 @default.
• W2176045506 hasOpenAccess W2176045506 @default.
• W2176045506 hasPrimaryLocation W21760455061 @default.
• W2176045506 hasRelatedWork W137242550 @default.
• W2176045506 hasRelatedWork W1589296438 @default.
• W2176045506 hasRelatedWork W1650680187 @default.
• W2176045506 hasRelatedWork W2043162780 @default.
• W2176045506 hasRelatedWork W2058119212 @default.
• W2176045506 hasRelatedWork W2090056693 @default.
• W2176045506 hasRelatedWork W2098715160 @default.
• W2176045506 hasRelatedWork W2152443897 @default.
• W2176045506 hasRelatedWork W2186902482 @default.
• W2176045506 hasRelatedWork W2608443800 @default.
• W2176045506 hasRelatedWork W2784178687 @default.
• W2176045506 hasRelatedWork W2897196027 @default.
• W2176045506 hasRelatedWork W2904329316 @default.
• W2176045506 hasRelatedWork W2959458829 @default.
• W2176045506 hasRelatedWork W3025742326 @default.
• W2176045506 hasRelatedWork W3088191730 @default.
• W2176045506 hasRelatedWork W3096270497 @default.
• W2176045506 hasRelatedWork W3116945527 @default.
• W2176045506 hasRelatedWork W3162451417 @default.
• W2176045506 hasRelatedWork W360836421 @default.
• W2176045506 isParatext "false" @default.
• W2176045506 isRetracted "false" @default.
• W2176045506 magId "2176045506" @default.
• W2176045506 workType "article" @default.